NMRA NEUMORA THERAPEUTICS INC

Neumora Therapeutics to Participate in Upcoming Conferences in November

Neumora Therapeutics to Participate in Upcoming Conferences in November

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November:

  • Guggenheim Healthcare Talks 5th Annual INI Conference: Members of management will participate in a fireside chat on Monday, November 6, 2023, at 1:50 PM ET in New York, NY.



  • Stifel 2023 Healthcare Conference: Members of management will participate in a fireside chat on Wednesday, November 15, 2023, at 11:30 AM ET in New York, NY.

A live webcast of each event will be available on the events and presentations section of the Company’s website at . A replay of the webcasts will be available following the completion of the events and will be archived for up to 30 days.

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Neumora’s therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora’s work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. For additional information, please visit  and follow on Twitter: .

Neumora Contact

Helen Rubinstein



315-382-3979



EN
30/10/2023

Underlying

NMRANEUMORA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUMORA THERAPEUTICS INC

 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and...

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period with up to six clinical data readouts in patients over the next 18 months, including Phase 3 ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Report Second Quarter 2025 Financial Results o...

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update. A live webcast of the event will be available on...

July 23, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of...

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced the initiat...

July 9, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Reports First Quarter 2025 Financial Results and ...

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 20...

May 12, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Report First Quarter 2025 Financial Results on...

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events a...

April 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch